Comparing the Surgical Outcomes of Intersphincteric Resection (ISR) and Transanal Total Mesorectal Excision (TATME) in Rectal Cancer: A Meta-Analysis

比较直肠癌括约肌间切除术(ISR)和经肛门全直肠系膜切除术(TATME)的手术疗效:一项荟萃分析

阅读:2

Abstract

Rectal cancer management has evolved significantly with the introduction of sphincter-preserving techniques, particularly intersphincteric resection (ISR) and transanal total mesorectal excision (TATME), aimed at improving oncologic safety while maintaining functional outcomes. Despite increasing use, comparative evidence remains limited. This meta-analysis evaluated surgical and oncologic outcomes of ISR versus TATME in patients with low rectal cancer. A comprehensive search of PubMed, Scopus, CENTRAL, ProQuest, and Google Scholar identified eligible randomized and observational studies published between January 2016 and March 2025. Five studies, including one randomized controlled trial, two propensity-matched analyses, and two comparative cohort studies, comprising 1,630 patients (ISR=802; TATME=828), were included. Pooled data demonstrated no significant difference in anastomotic leakage rates between ISR and TATME (OR=0.86; 95% CI: 0.58-1.26; p=0.42) and similar circumferential resection margin positivity (OR=0.91; 95% CI: 0.62-1.33; p=0.62), indicating comparable oncologic quality. Local recurrence rates were also equivalent (OR=0.94; 95% CI: 0.64-1.39; p=0.77). However, TATME demonstrated a significantly lower rate of postoperative complications (OR=0.61; 95% CI: 0.44-0.84; p=0.003), suggesting improved short-term recovery. Conversely, TATME required longer operative time compared with ISR (OR=1.74; 95% CI: 1.30-2.32; p=0.0002), likely reflecting technical demands and the learning curve. Overall, both techniques achieved comparable oncologic safety, with TATME offering reduced postoperative morbidity at the cost of increased operative duration. These findings support TATME as a safe and effective alternative to ISR in specialized centers with appropriate expertise. Future large-scale randomized trials with long-term follow-up are required to validate functional outcomes and refine patient selection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。